Thalidomide in Treating Patients With Myelofibrosis
NCT00015821
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
43
Enrollment
NIH
Sponsor class
Conditions
Primary Myelofibrosis
Interventions
DRUG:
thalidomide
OTHER:
laboratory biomarker analysis
Sponsor
National Cancer Institute (NCI)